Form 4: Protara Therapeutics Director Richard S. Levy Acquires 20,000 Shares

Director Richard S. Levy of Protara Therapeutics, Inc. purchased 20,000 shares of common stock at an average price of $3.19 on May 14, 2025.

Summary

• On May 14, 2025, Richard S. Levy, a director of Protara Therapeutics, Inc., acquired 20,000 shares of common stock.
• The shares were purchased at a weighted average price of $3.19.
• Following the transaction, Levy directly owns 51,000 shares of Protara Therapeutics common stock.

Sentiment

Score: 6

Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's prospects, but the transaction is relatively small and may not be highly significant.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The stock purchase by a director could positively influence shareholder sentiment.

Key Dates

Keywords

Protara Therapeutics, Richard S. Levy, stock acquisition, Form 4, insider trading, TARA